Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
53345-0037-01 53345-0037 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 25, 2018 In Use
51013-0190-09 51013-0190 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 29, 2018 In Use
51013-0190-30 51013-0190 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 29, 2018 In Use
70771-1347-03 70771-1347 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 16, 2018 In Use
70771-1347-09 70771-1347 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 16, 2018 In Use
70518-2378-00 70518-2378 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 23, 2019 Jan. 17, 2020 No Longer Used
70518-2378-02 70518-2378 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan. 3, 2020 Oct. 28, 2020 No Longer Used
70362-0702-39 70362-0702 Dexamethasone 1.5 mg Dxevo 1.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 25, 2019 In Use
70569-0151-11 70569-0151 Dexamethasone Dxevo 1.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 17, 2019 In Use
70362-0707-39 70362-0707 Dexamethasone 1.5 mg Dxevo 1.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 25, 2019 April 29, 2019 No Longer Used
72903-0853-01 72903-0853 Mirvetuximab soravtansine ELAHERE 5.0 mg/mL Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 Intravenous Nov. 14, 2022 In Use
82705-0002-01 82705-0002 Epcoritamab-bysp EPKINLY 4.0 mg/.8mL Immunotherapy Monoclonal Antibody CD20, CD3 Subcutaneous May 19, 2023 In Use
82705-0010-01 82705-0010 Epcoritamab-bysp EPKINLY 48.0 mg/.8mL Immunotherapy Monoclonal Antibody CD20, CD3 Subcutaneous May 19, 2023 In Use
00143-9167-01 00143-9167 Eribulin mesylate ERIBULIN MESYLATE 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous June 28, 2024 In Use
59676-0600-12 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 14, 2018 In Use
59676-0600-56 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral April 1, 2019 In Use
59676-0600-99 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 14, 2018 Nov. 30, 2019 In Use
59676-0604-14 59676-0604 Apalutamide ERLEADA 240.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 17, 2023 In Use
59676-0604-30 59676-0604 Apalutamide ERLEADA 240.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 17, 2023 In Use
31722-0263-30 31722-0263 ERLOTINIB ERLOTINIB 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
31722-0264-30 31722-0264 ERLOTINIB ERLOTINIB 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
31722-0265-30 31722-0265 ERLOTINIB ERLOTINIB 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
62332-0565-30 62332-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0565-90 62332-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0566-30 62332-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use

Found 10,000 results in 5 milliseconds — Export these results